Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

2.71
+0.07002.65%
Post-market: 2.710.00000.00%16:10 EST
Volume:19.84K
Turnover:54.07K
Market Cap:30.31M
PE:-1.55
High:2.79
Open:2.64
Low:2.61
Close:2.64
52wk High:5.74
52wk Low:2.53
Shares:11.18M
Float Shares:8.59M
Volume Ratio:0.32
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7524
EPS(LYR):-1.9309
ROE:-104.58%
ROA:-55.99%
PB:3.16
PE(LYR):-1.40

Loading ...

BRIEF-Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation For Soft Tissue Sarcomas

Reuters
·
Jan 20

Lantern Pharma's Lp-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

THOMSON REUTERS
·
Jan 20

Lantern Pharma’s treatment of soft tissue sarcoma granted orphan designation

TIPRANKS
·
Jan 16

Lake Street Remains a Buy on Lantern Pharma (LTRN)

TIPRANKS
·
Jan 13

Lantern Pharma establishes India AI center to industrialize RADR platform

TIPRANKS
·
Jan 12

BRIEF-Lantern Pharma Inc - Establishes Ai Center Of Excellence In Bengaluru

Reuters
·
Jan 12

Lantern Pharma Inc - Hiring Initiated, Expansion Expected to Be Cash Flow Neutral

THOMSON REUTERS
·
Jan 12

Lantern Pharma Inc - Phase 2 Focuses on Multi-Disease Expansion and Revenue Acceleration

THOMSON REUTERS
·
Jan 12

Lantern Pharma Inc - Establishes AI Center of Excellence in Bengaluru

THOMSON REUTERS
·
Jan 12

Lantern Pharma Unveils AI Center of Excellence and Major Platform Rollout at Investor and Analyst Event

Reuters
·
Jan 12

Lantern Pharma Inc: Clinical Trial Met All Primary Endpoints for Safety, Tolerability, and Established a Clear Recommended Phase 2 Dose

THOMSON REUTERS
·
Dec 03, 2025

Lantern Pharma : Reports Additional Positive Lp-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients

THOMSON REUTERS
·
Dec 03, 2025

Lantern Pharma Reports Positive Phase 1a Results for LP-184 in Advanced Solid Tumors

Reuters
·
Dec 03, 2025

Lantern Pharma’s Q3 2025: Clinical and AI Progress

TIPRANKS
·
Nov 14, 2025

Lantern Pharma posts Q3 net loss of $4.2 million as LP-184 trial meets primary endpoints

Reuters
·
Nov 13, 2025

Lantern Pharma Inc Qtrly Net Loss $0.39 per Share

THOMSON REUTERS
·
Nov 13, 2025

Press Release: Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates

Dow Jones
·
Nov 13, 2025

Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate

Benzinga
·
Nov 13, 2025

Lantern Pharma management to meet virtually with Lake Street

TIPRANKS
·
Nov 12, 2025

Lantern Pharma CEO Showcases AI-Driven Oncology Advances on Bloomberg

Reuters
·
Nov 10, 2025